MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keac144

Медицинская библиотека · Rheumatology (Oxford, England) · 2022

Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation.

Shelly Shahar, Beecher Grayson, Milone Margherita, Liewluck Teerin, Ernste Floranne, Triplett James, Naddaf Elie, Zekeridou Anastasia, McKeon Andrew, Pittock Sean J, Dubey Divyanshu, Mills John R, Mandrekar Jay, Klein Christopher J

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

To investigate immune-mediated necrotizing myopathy (IMNM) association with cancer and its clinical implications.

METHODS

IMNM cases were identified 1 January 2000 to 31 December 2020 matching sex and age controls (4:1).

RESULTS

A total of 152 patients with IMNM were identified and among serologically tested, 60% (83/140) were HMGCR-IgG+, 14% (20/140) were SRP-IgG+ and 26% (37/140) were seronegative. Cancer rates were not significantly different between serological subgroups; 18.1% (15/83) HMGCR-IgG+, 25% (5/20) SRP-IgG+ and 30% (11/37) seronegative (P = 0.34). Cancer screening was performed within 12 months from IMNM diagnosis in 88% (134/152) (whole-body CT plus FDG-PET CT in 53, CT alone in 72 and FDG-PET alone in 9). FDG-PET/CT was positive in 73% (25/34) of cancers. Increasing age was the only risk associated with cancer (P = 0.02). The odds of developing cancer at ±3 or ±5 years from IMNM diagnosis was not higher than controls (OR = 0.49; CI: 0.325-0.76). Lifetime IMNM diagnosis of cancer was less compared with controls (OR = 0.5 CI: 0.33-0.78, P = 0.002). Most patients responded to treatment (137/147, P < 0.001). Death and treatment response did not significantly differ between cancer [23% (8/34); 88% (29/33)] and non-cancer patients [19% (23/118); 92% (108/118)]. In total, 13% (20/152) of patients died during follow-up compared with 14% (41/290) of medicine and 16% (46/290) of neurology controls (P = 0.8). Seropositives had greater life expectancy than seronegatives (P = 0.01).

CONCLUSIONS

Greater cancer risk is not observed in IMNM vs controls. Cancer screening in IMNM should be individualized based on age-personal and family history, including consideration of FDG-PET/CT. Immune-treatment response did not differ with cancer.

Для цитирования: Shelly Shahar, Beecher Grayson, Milone Margherita, Liewluck Teerin, Ernste Floranne, Triplett James, Naddaf Elie, Zekeridou Anastasia, McKeon Andrew, Pittock Sean J, Dubey Divyanshu, Mills John R, Mandrekar Jay, Klein Christopher J. Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation.. Rheumatology (Oxford, England). 2022. DOI: 10.1093/rheumatology/keac144.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.